JP2014527408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527408A5 JP2014527408A5 JP2014525261A JP2014525261A JP2014527408A5 JP 2014527408 A5 JP2014527408 A5 JP 2014527408A5 JP 2014525261 A JP2014525261 A JP 2014525261A JP 2014525261 A JP2014525261 A JP 2014525261A JP 2014527408 A5 JP2014527408 A5 JP 2014527408A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- region
- variable region
- iglv3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 49
- 229920001184 polypeptide Polymers 0.000 claims 47
- 102000004196 processed proteins & peptides Human genes 0.000 claims 47
- 210000004027 cell Anatomy 0.000 claims 20
- 108091033319 polynucleotide Proteins 0.000 claims 17
- 102000040430 polynucleotide Human genes 0.000 claims 17
- 239000002157 polynucleotide Substances 0.000 claims 17
- 238000000034 method Methods 0.000 claims 15
- 230000001580 bacterial effect Effects 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 7
- 101001005360 Homo sapiens Immunoglobulin lambda variable 3-1 Proteins 0.000 claims 6
- 102100025921 Immunoglobulin lambda variable 3-1 Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 101001054843 Homo sapiens Immunoglobulin lambda variable 1-40 Proteins 0.000 claims 5
- 101001054838 Homo sapiens Immunoglobulin lambda variable 1-44 Proteins 0.000 claims 5
- 101001054837 Homo sapiens Immunoglobulin lambda variable 1-47 Proteins 0.000 claims 5
- 101001005364 Homo sapiens Immunoglobulin lambda variable 3-19 Proteins 0.000 claims 5
- 101000978133 Homo sapiens Immunoglobulin lambda variable 6-57 Proteins 0.000 claims 5
- 102100026911 Immunoglobulin lambda variable 1-40 Human genes 0.000 claims 5
- 102100026921 Immunoglobulin lambda variable 1-44 Human genes 0.000 claims 5
- 102100026809 Immunoglobulin lambda variable 1-47 Human genes 0.000 claims 5
- 102100025937 Immunoglobulin lambda variable 3-19 Human genes 0.000 claims 5
- 102100023747 Immunoglobulin lambda variable 6-57 Human genes 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002824 mRNA display Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000001322 periplasm Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 238000002702 ribosome display Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011903298 | 2011-08-18 | ||
| AU2011903298A AU2011903298A0 (en) | 2011-08-18 | Soluble polypeptides | |
| PCT/AU2012/000970 WO2013023251A1 (en) | 2011-08-18 | 2012-08-17 | Soluble polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527408A JP2014527408A (ja) | 2014-10-16 |
| JP2014527408A5 true JP2014527408A5 (enExample) | 2016-06-16 |
| JP6244301B2 JP6244301B2 (ja) | 2017-12-06 |
Family
ID=47714621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014525261A Active JP6244301B2 (ja) | 2011-08-18 | 2012-08-17 | 可溶性ポリペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10087261B2 (enExample) |
| EP (1) | EP2744931B1 (enExample) |
| JP (1) | JP6244301B2 (enExample) |
| CN (1) | CN103890246A (enExample) |
| CA (1) | CA2845391C (enExample) |
| DK (1) | DK2744931T3 (enExample) |
| ES (1) | ES2682254T3 (enExample) |
| WO (1) | WO2013023251A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2744931T3 (en) | 2011-08-18 | 2018-08-06 | Affinity Biosciences Pty Ltd | SOLUBLE POLYPEPTIDES |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| HRP20191865T1 (hr) | 2013-01-14 | 2020-01-10 | Xencor, Inc. | Novi heterodimerni proteini |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| CA2901385A1 (en) * | 2013-02-20 | 2014-08-28 | Affinity Biosciences Pty Ltd | Cytoplasmic expression of fab proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP3587448B1 (en) * | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| EP3954713A3 (en) | 2014-03-28 | 2022-03-30 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| IL278574B2 (en) | 2014-11-12 | 2024-11-01 | Seagen Inc | Glycan-interacting compounds and methods of use |
| CN116333153A (zh) | 2014-11-26 | 2023-06-27 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| PE20240142A1 (es) | 2015-08-19 | 2024-02-01 | Pfizer | Anticuerpos inhibidores via del factor tisular y usos de los mismos |
| WO2017083582A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
| IL263542B2 (en) | 2016-06-14 | 2024-10-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
| KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| KR20240044544A (ko) | 2017-03-03 | 2024-04-04 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| AU2018383600B2 (en) | 2017-12-11 | 2025-10-02 | Abalone Bio, Inc. | Yeast display of proteins in the periplasmic space |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| AU2020232605A1 (en) | 2019-03-01 | 2021-10-21 | Xencor, Inc. | Heterodimeric antibodies that bind ENPP3 and CD3 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| FI101678B1 (fi) | 1990-12-31 | 1998-08-14 | Akzo Nv | Happolabiileja kytkentämolekyylejä |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| IT1307309B1 (it) | 1999-12-30 | 2001-10-30 | Enea Ente Nuove Tec | Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono. |
| DE60144063D1 (de) * | 2000-12-18 | 2011-03-31 | Dyax Corp | Gerichtete bibliotheken die genetisch verpackt sind |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| CN103739706B (zh) | 2002-05-22 | 2015-11-18 | 艾斯巴技术-诺华有限责任公司 | 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 |
| CA2490280A1 (en) * | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| KR20120133403A (ko) | 2004-06-01 | 2012-12-10 | 도만티스 리미티드 | 증강된 혈청 반감기를 가지는 이특이성 융합 항체 |
| EP2331570B1 (en) | 2008-09-10 | 2014-08-27 | Philochem AG | Display library for antibody selection |
| EP2356270B1 (en) * | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| US8716196B2 (en) | 2009-05-20 | 2014-05-06 | Novimmune S.A. | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
| CN102459591B (zh) | 2009-05-20 | 2015-05-13 | 诺维莫尼公司 | 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法 |
| NZ596603A (en) | 2009-05-29 | 2013-07-26 | Morphosys Ag | A collection of antibodies or fragments having properties relevant to developability |
| FR2945961B1 (fr) | 2009-05-29 | 2012-07-13 | Air Liquide | Epuration d'un gaz contenant des oxydes d'azote |
| CA2785359C (en) | 2009-12-23 | 2019-12-31 | Affinity Biosciences Pty Ltd | Protein display |
| JP5195798B2 (ja) * | 2010-03-23 | 2013-05-15 | 豊田合成株式会社 | 半導体発光素子の製造方法 |
| ES2609313T3 (es) | 2011-06-29 | 2017-04-19 | Affinity Biosciences Pty Ltd | Método de expresión de proteínas |
| DK2744931T3 (en) | 2011-08-18 | 2018-08-06 | Affinity Biosciences Pty Ltd | SOLUBLE POLYPEPTIDES |
| CA2901385A1 (en) | 2013-02-20 | 2014-08-28 | Affinity Biosciences Pty Ltd | Cytoplasmic expression of fab proteins |
| US9705121B2 (en) | 2014-08-18 | 2017-07-11 | Johnson Controls Technology Company | Lead frame for a battery module |
-
2012
- 2012-08-17 DK DK12824386.2T patent/DK2744931T3/en active
- 2012-08-17 CN CN201280047892.XA patent/CN103890246A/zh active Pending
- 2012-08-17 WO PCT/AU2012/000970 patent/WO2013023251A1/en not_active Ceased
- 2012-08-17 EP EP12824386.2A patent/EP2744931B1/en active Active
- 2012-08-17 JP JP2014525261A patent/JP6244301B2/ja active Active
- 2012-08-17 CA CA2845391A patent/CA2845391C/en active Active
- 2012-08-17 ES ES12824386.2T patent/ES2682254T3/es active Active
-
2014
- 2014-02-14 US US14/181,026 patent/US10087261B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527408A5 (enExample) | ||
| Mimmi et al. | Phage display: an overview in context to drug discovery | |
| JP2016531924A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| CN106047857A (zh) | 一种发掘特异性功能抗体的方法 | |
| CN102952191A (zh) | 全人源抗cd33单链抗体zjl101及其应用 | |
| CN104926941A (zh) | 牛源性抗金黄色葡萄球菌基因工程单链抗体、制备方法及其用途 | |
| CN106928363B (zh) | 一种FAP纳米抗体Nb12 | |
| Contreras-Martínez et al. | Intracellular ribosome display via SecM translation arrest as a selection for antibodies with enhanced cytosolic stability | |
| Mustafa et al. | Development of recombinant antibody by yeast surface display technology | |
| CN106928364B (zh) | 一种FAP纳米抗体Nb26 | |
| Yang et al. | Fully human recombinant antibodies against EphA2 from a multi-tumor patient immune library suitable for tumor-targeted therapy | |
| CN106928365B (zh) | 一种FAP纳米抗体Nb36 | |
| JP2019068837A (ja) | 標的分子に結合するポリペプチドの決定方法及び決定システム | |
| CN117106082B (zh) | 一种抗TGFβ的人源化纳米抗体 | |
| Sun et al. | A fine-tuned yeast surface-display/secretion platform enables the rapid discovery of neutralizing antibodies against Clostridioides difficile toxins | |
| Fagète et al. | Dual display: phage selection driven by co-engagement of two targets by two different antibody fragments | |
| CN106928368B (zh) | 一种FAP纳米抗体Nb57 | |
| Li et al. | Phage display screening of TIGIT-specific antibody for antitumor immunotherapy | |
| Schofield et al. | Genetic methods of antibody generation and their use in immunohistochemistry | |
| Motallebnezhad et al. | Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells | |
| Li et al. | Preparation and interaction mechanism analysis of single-chain fragment variables against phenylethanolamine A | |
| CN106928355A (zh) | 一种CD105纳米抗体Nb184 | |
| Csepregi et al. | The physiological landscape and specificity of antibody repertoires are consolidated by multiple immunizations | |
| CN113651889B (zh) | 一种抗EphA2全人源双价重组抗体scFv-Fc |